Growing Prevalence of Autoimmune Diseases to Fuel $10,012.9 Million Revenue in Autoimmune Disease Diagnostics Market in 2030

The rising incidence of autoimmune diseases, growing geriatric population, advent of novel biomarkers, increasing initiatives being taken by various government and private organizations for raising public awareness about autoimmune diseases, and the soaring strategic development projects and activities being launched by the market players are the key factors fueling the expansion of the global autoimmune disease diagnostics market. Furthermore, the market is predicted to attain a valuation of $10,012.9 million in 2030, exhibiting a CAGR of 8.5% from 2020 to 2030.

To learn more about this report: https://bit.ly/2UTn0DC

Based on product, the autoimmune disease diagnostics market is categorized into instruments and consumables and assay kits. Of these, the consumables and assay kits category is predicted to dominate the market in the future years, on account of the growing incidence of autoimmune diseases and the rising requirement for tests, such as enzyme-linked immunosorbent assay (ELISA), rheumatoid factor (RF) & anti-cyclic citrullinated peptide (CCP) antibody, and antinuclear antibody (ANA) immunofluorescence assay (IFA).

Globally, the North American autoimmune disease diagnostics market is predicted to exhibit lucrative growth in the upcoming years, owing to the rapid improvements in healthcare facilities and infrastructure, growing prevalence of autoimmune diseases, rising research activities, soaring geriatric population, and the existence of several leading market players in the region.

Browse full report at: https://www.psmarketresearch.com/market-analysis/autoimmune-disease-diagnostics-market-report

Some of the major market players are A. Menarini Diagnostics S.r.l., Bio-Rad Laboratories Inc., Adaltis S.r.l., Sigma Diagnostics Inc., ORGENTEC Diagnostika GmbH, PerkinElmer Inc., Inova Diagnostics, ELITech Group, Grifols S.A., HYCOR Biomedical, Exagen Inc., Cambridge Life Sciences Limited, Trinity Biotech plc, DiaSorin S.p.A., F. Hoffmann-La Roche Ltd., Seramun Diagnostica GmbH, Siemens AG, bioMérieux S.A., Thermo Fisher Scientific Inc., Danaher Corporation, and Abbott Laboratories.